Futibatinib

Futibatinib is a novel, oral, selective, and reversible tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor 1 (FGFR1). It was developed by FibroGen, Inc. and is currently being evaluated in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC). The drug works by blocking the activity of FGFR1, a protein involved in cell growth, survival, and proliferation. This action is thought to inhibit tumor growth and potentially lead to tumor regression. In addition, it may help reduce side effects associated with chemotherapy, such as nausea and fatigue.

Futibatinib is a medication used to treat a specific type of cancer: cholangiocarcinoma.

Cholangiocarcinoma is a cancer that forms in the bile ducts, the tubes that carry bile from the liver to the small intestine. Futibatinib is only approved for a particular type of cholangiocarcinoma:

• Intrahepatic cholangiocarcinoma: This refers to cancer that starts in the bile ducts within the liver.

How it Works:

• Futibatinib belongs to a class of drugs called kinase inhibitors.
• Kinases are enzymes that play a critical role in cell growth and division.
• In some cases of cholangiocarcinoma, there are genetic alterations involving a protein called fibroblast growth factor receptor 2 (FGFR2).
• Futibatinib targets and inhibits FGFR2, thereby interrupting the uncontrolled growth and spread of cancer cells.

Who Can Take Futibatinib:

• Futibatinib is specifically for adults with previously treated intrahepatic cholangiocarcinoma.
• This means the cancer has progressed after receiving other forms of treatment.
• Additionally, the cancer must have FGFR2 gene fusions or other rearrangements. A doctor will perform a specific genetic test to confirm this.

Possible Side Effects:

• Like most medications, Futibatinib can cause side effects. Some common ones include:
  • Fatigue
  • Diarrhea
  • Constipation
  • Nausea or vomiting
  • Dry mouth
  • Hair loss
  • Changes in taste
  • Muscle or joint pain
  • Skin or nail problems
• It's important to talk to your doctor about any side effects you experience.

Important Considerations:

• Futibatinib is a relatively new medication (approved in the US in 2022) and is still under investigation.
• It can interact with other medications, so be sure to tell your doctor about all your medications and supplements before starting Futibatinib.
• Women who are pregnant or breastfeeding should not take Futibatinib due to potential harm to the fetus or infant.

Overall, Futibatinib is a promising treatment option for adults with a specific type of cholangiocarcinoma. However, it's important to discuss the potential benefits and risks with your doctor to determine if it's the right course of treatment for you.